The Dow Jones Industrial Average reached a record high following a modest inflation report, spurring hopes for additional ...

The blue-chip Dow Jones Industrial Average closed at a record high today as investors welcomed a subdued inflation report ...

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

The Dow Jones Industrial Average closed at a record high, driven by investor optimism following a subdued inflation report.

In a breakthrough for people with schizophrenia, the FDA has approved a new oral medication for adults. Unlike traditional antipsychotic drugs, the medication, which will be marketed under the name ...

Bristol Myers trades higher after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter ...

Studies showed Bristol Myers Squibb's drug, KarXT, improved symptoms of schizophrenia and led to fewer side effects than existing antipsychotic treatments. Researchers are optimistic patients might ...

The Dow jumped more than 400 points Friday to an all-time high after a benign inflation report cleared the way for the ...

British scientists have hailed the US approval of a new drug for schizophrenia, saying it “has the potential to change the ...

The agency is considering whether to limit the indications of Keytruda, Opdivo, and Tevimbra to PD-L1-positive patients amid testing uncertainties.

Experts expressed enthusiasm Friday after US health regulators approved the first new form of treatment for schizophrenia in decades.